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Conclusion Patients ≥ 80 years experienced high rates of 
ischaemic and bleeding complications; especially in this 
high-risk patient group individualised therapy is needed to 
optimise clinical outcomes.
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Introduction
For patients with ST-segment elevation myocardial infarc-
tion (STEMI), primary percutaneous coronary intervention 
(PCI) is the preferred therapy [1, 2]. Guidelines have been 
composed to suggest optimal antithrombotic and antiplate-
let regimens in order to prevent new ischaemic events while 
balancing the risk of bleeding events [2, 3]. However, due to 
the frailty that comes with advanced age, the higher preva-
lence of diverse comorbidities in the elderly, and the fact 
that large clinical trials often list age ≥ 80years as an exclu-
sion criterion, it is currently unclear if following guideline 
recommendations will also result in acceptable outcomes 
regarding ischaemic and bleeding endpoints in elderly 
patients undergoing primary PCI.
The mean age of the population in the developed world 
is increasing rapidly [4]. In the European Union, the pro-
portion of people aged ≥ 80years is expected to triple from 
4.8 to 12.0 % between 2010 and 2060 [5]. An increase in 
the absolute and relative number of octogenarians under-
going primary PCI has been described [6]. A small num-
ber of observational studies have reported mortality rates 
after primary PCI for STEMI in patients aged ≥ 80 years 
[6–9]. However, there is a paucity of data on the long-term 
occurrence of recurrent ischaemic events and bleeding in 
the elderly after primary PCI.
Abstract
Background The population is ageing rapidly and the pro-
portion of patients aged ≥ 80 years undergoing primary per-
cutaneous coronary intervention (PCI) is rising, but clinical 
trials have primarily been performed in younger patients.
Methods Patients undergoing primary PCI between 2003 
and 2008 were subdivided into 3 groups: < 60, 60-79, and 
≥ 80 years. Endpoints at 3-year follow-up included all-cause 
mortality, recurrent myocardial infarction (reMI), stent 
thrombosis, target lesion revascularisation (TLR), bleeding 
(BARC bleeding ≥ 3), stroke, and major adverse cardio-
vascular events (MACE, a composite of cardiac mortality, 
reMI, stroke and TLR).
Results 2002 patients with ST-segment elevation myocar-
dial infarction (STEMI) were included, 885 (44.2 %) aged 
< 60, 921 (46.0 %) 60–79, and 196 (9.7 %) ≥ 80 years. Co-
morbidities such as diabetes mellitus, prior stroke, malig-
nant disease, anaemia, and chronic kidney disease were 
more prevalent in patients ≥ 80 years. The incidence of both 
ischaemic and bleeding events strongly increased with age. 
Age ≥ 80 years was an independent predictor of mortality 
(HR 2.56, 95 % CI1.69–3.87, p < 0.001), a borderline non-
significant predictor of overall bleeding (HR 1.38, 95 %CI 
0.95–2.00, p = 0.088), and a significant predictor of non-ac-
cess site bleeding (HR 2.26, 95 %CI 1.46–3.51, p < 0.001).
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We therefore investigated a cohort of STEMI patients 
undergoing primary PCI in a large tertiary care centre to pro-
vide more insight into ischaemic and bleeding outcomes after 
primary PCI for STEMI in patients aged 80 years and older.
Methods
Data analysed in this study were obtained from STEMI 
patients who were accepted for primary PCI at the Aca-
demic Medical Center–University of Amsterdam between 
1 January 2003, and 31 July 2008. The study complied with 
the Declaration of Helsinki, and the local ethics committee 
approved the study protocol. In general, patients qualified 
for primary PCI if they had typical ischaemic chest pain and 
at least 1 mm ST-segment elevation in two or more con-
tiguous leads or a new left bundle branch block (LBBB). 
The primary PCI and adjunctive pharmacological treat-
ment were performed according to the American College of 
Cardiology/American Heart Association and the European 
Society of Cardiology (ESC) guidelines. Patients received 
a standard 300–600 mg clopidogrel loading dose. If a coro-
nary stent was implanted, clopidogrel was prescribed for at 
least one month to patients with a bare metal stent (BMS) 
and for 6 to 12 months to patients with a drug-eluting stent 
(DES).Patients were routinely pretreated with 300–500 mg 
aspirin and 5000 IU unfractionated heparin (UFH). Glyco-
protein IIb/IIIa inhibitors (GPIs) were used in a bail-out set-
ting at the discretion of the operator.
A detailed description of the study protocol has been pre-
viously published [10–12]. In short, procedural and angio-
graphic data were prospectively collected by interventional 
cardiologists and specialised nurses in a dedicated data-
base. We obtained follow-up of clinical outcome, includ-
ing recurrent MI, stroke, stent thrombosis and bleeding, by 
reviewing inpatient and outpatient charts in the tertiary PCI 
centre and referring hospitals between 2011 and 2012 for 
consecutive STEMI patients with available activated partial 
thromboplastin time (aPTT) measurements in the context 
of a study designed to investigate the relationship between 
aPTT and clinical outcome in STEMI patients treated with 
primary PCI. Follow-up of clinical events was censored at 
the date of chart review. Patients whose whereabouts were 
unknown were considered lost to follow-up from the date of 
last known medical contact. Follow-up information regard-
ing vital status was obtained from computerised, long-term 
mortality records from the National Death Index between 1 
December 2012 and 30 April 2012.
Study design
The study cohort consisted of all STEMI patients included 
in our study database who were alive at the end of the pro-
cedure. Clinical outcomes included major adverse cardiac 
events (MACE; a composite of cardiac death, recurrent 
myocardial infarction (MI), stroke and target lesion revas-
cularisation (TLR)), all-cause, cardiac and non-cardiac mor-
tality, recurrent MI, ischaemic and haemorrhagic stroke, 
stent thrombosis, TLR and bleeding. Cardiac death, recur-
rent MI, stent thrombosis and TLR were defined accord-
ing to the Academic Research Consortium (ARC) criteria 
[13]. Bleeding complications were defined according to the 
Bleeding Academic Research Consortium (BARC) bleeding 
classification and the Thrombolysis In Myocardial Infarc-
tion bleeding classification [14, 15] Stroke was defined 
as an irreversible neurological deficit, as classified by the 
treating neurologist, on the basis of supporting information, 
including brain images and neurological evaluation.
Statistical analysis
Normally distributed continuous variables are reported as 
the mean with standard deviation and compared with the 
one-way ANOVA test, skewed distributed variables are 
presented as the median with interquartile range (IQR) 
and compared with the Kruskal-Wallis test. Categorical 
variables are presented as proportions and compared with 
the χ2 test for trend. Event rates of clinical outcomes were 
estimated using Kaplan-Meier analyses. Missing covariate 
data were imputed with the use of multiple imputations and 
were assumed to be missing at random. We performed 10 
imputations using the Markov Chain Monte Carlo method. 
Cox proportional hazards models were first fit separately in 
the 10 imputed datasets and subsequently pooled according 
to Rubin’s protocol [16]. Multivariable Cox proportional 
hazards regression was used in the following manner: first, 
univariable hazard ratios were calculated for all variables in 
Tables 1 and 2. Then, multivariable backward stepwise Cox 
regression models were constructed using variables with 
p < 0.10 in univariate analysis as candidate variables. Entry 
and exit criteria were set at p = 0.10.
In order to plot the graphic relationships between age and 
probability of death, MACE, BARC type ≥ 3 bleeding and 
stroke at 3 years, we calculated the predicted probability of 
these events by incorporating the coefficients returned by 
the unadjusted and adjusted Cox models in the following 
equation:
Where S(t) is the predicted event-free survival at timepoint 
t, H0(t) is the baseline hazard at time t, x1, 2, … k is the vector of 
the covariates, and β
1, 2, … k
 the coefficients determined from 
the Cox regression models. The risk of adverse events was 
S t e H t x x xo k k( )= − ( ) + +…( )( )* 1 1 2 2β β β
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sis and target lesion revascularisation decreased non-signif-
icantly with age.
Table 1 of the Supplementary Appendix shows the results 
of multivariable Cox regression analyses for 3-year clini-
cal outcomes. Relative to patients aged < 60 years, patients 
aged 60–79 years and those aged ≥ 80 years were found to 
have an increased risk of cardiac and non-cardiac mortal-
ity, stroke and non-access site bleeding after correction for 
confounding variables. In addition, age 60–79 years and age 
≥ 80 years was associated with a borderline non-significant 
increase in risk of BARC type ≥ 3 bleeding. On the other 
hand, age ≥ 80 years was not an independent predictor of 
MACE. Detailed multivariable models are shown in the 
Supplementary Appendix.
Age as a continuous variable was an independent pre-
dictor of all-cause mortality (1.43 per 10 year increase; 
95 % CI 1.27–1.61; p < 0.001), cardiac mortality (HR 1.34; 
95 % CI 1.17–1.53, p < 0.001), non-cardiac mortality (HR 
1.55; 95 % CI 1.24–1.95, p < 0.001), stroke (HR 1.46; 95 % 
CI 1.18–1.80; p < 0.001) and BARC type ≥ 3 bleeding (HR 
1.15; 95 % CI 1.04–1.26; p = 0.006), but not of MACE (HR 
1.06; 95 % CI 0.98–1.16; p = 0.17), or recurrent MI (HR 
1.04; 95 % CI 0.93–1.17, p = 0.49) (Supplementary Appen-
dix, Table 2). Figure 3 shows a graphic representation of 
the unadjusted (left panel) and adjusted (right panel) rela-
tion between age as a continuous variable and the hazard 
of MACE, mortality, BARC bleeding ≥ 3, and stroke up to 
3-year follow-up.
Discussion
The current study extends previous reports by providing 
insight into the occurrence of a large number of clinically 
relevant endpoints in up to 3 years of follow-up in patients 
undergoing primary PCI according to age. We found higher 
rates of ischaemic and haemorrhagic endpoints with increas-
calculated as 1 min S(t). For the present analysis, we assumed 
‘t’ to be 1095 days for all patients. The predicted probabili-
ties were pooled over the imputed datasets utilising Rubin’s 
protocol after applying the logit transformation to the pre-
dicted probabilities [17]. The relationship between age and 
the probability of death, MACE, stroke and bleeding were 
plotted graphically using a model fitting approach involv-
ing cubic polynomials (splines) as previously employed by 
the GUSTO-I (Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary Arteries) 
trial investigators [18]. All analyses were performed with 
Statistical Package for Social Sciences software (SPSS ver-
sion 19.0, Chicago, Illinois).
Results
Of 2009 STEMI patients recorded in our database who were 
treated with primary PCI in our institution between 1 Janu-
ary 2003 and 31 July 2008, 2002 were alive at the end of 
the procedure. Median follow-up duration in this cohort of 
patients was 4.9 years (IQR 3.4–6.4 years). A total of 196 
patients were aged 80 years or older (9.7 %), 921 patients 
were aged 60–79 years (46.0 %), and 885 patients were aged 
< 60 years (44.2 %).
Baseline characteristics are shown in Table 1. The pro-
portion of female patients increased with age; among 
patients aged ≥ 80 years the majority of patients were 
female. Patients aged ≥ 80 years were more likely to have 
diabetes mellitus, prior coronary artery bypass graft surgery 
(CABG), a history of stroke or transient ischaemic event, 
peripheral artery disease and malignant disease compared 
with younger patients. Moreover, they more often had 
anaemia and an estimated creatinine clearance of < 60 ml/
min/1.73 m2. On the other hand, patients aged ≥ 80 years 
were less likely to be smokers, less often had a positive 
family history of coronary artery disease and had lower 
rates of hypercholesterolaemia at admission compared with 
younger patients.
Angiographic and procedural characteristics are shown 
in Table 2. Patients aged ≥ 80 years had longer ischaemic 
times, a higher prevalence of cardiogenic shock at admis-
sion, lower rates of post-procedural TIMI 3 flow, a higher 
rate of coronary calcification, multivessel disease and 
chronic total occlusions in non-infarct related vessels com-
pared with younger patients.
Figure 1 displays a Kaplan-Meier time-to-event curve 
for MACE. Figure 2 displays Kaplan-Meier time-to-event 
curves for recurrent MI, mortality, BARC bleeding ≥ 3, 
and stroke. Table 3 shows Kaplan-Meier estimates of the 
incidence of adverse events at 3-year follow-up. Rates of 
MACE, mortality, recurrent MI, stroke and BARC bleeding 
≥ 3 increased with age. Conversely, rates of stent thrombo-
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thrombosis or to undergo target lesion revascularisation 
[19, 20]. The fact that the rate of recurrent MI was higher 
among elderly patients suggests that recurrent MI in elderly 
patients is the result of plaque rupture of non-target lesions, 
and is likely explained by the more extensive atherosclero-
sis among the elderly.
The incidence of both access site and non-access site 
bleeding strongly increased with age in this study. Well-
known risk factors for bleeding such as female gender and 
chronic kidney disease were more prevalent in the elderly 
[21]. Moreover, advanced age is associated with increased 
vascular fragility and calcification, which are known risk 
factors for access site bleeding [22, 23]. In the current study, 
age ≥ 80 years was independently associated with non-
ing age, illustrating the frailty of this rapidly growing high-
risk patient group.
In a recent large registry, Velders et al. found an increased 
risk of early mortality and heart failure in patients aged ≥ 80 
as compared with patients younger than 80 [8]. However, 
among the elderly patients who survived the first month(s), 
the prognosis was similar compared with their younger 
counterparts. This indicates that the difference in mortality 
between patients aged ≥ 80 and their younger counterparts 
can be explained by the direct adverse consequence of the 
STEMI itself, such as arrhythmia, heart failure, mechani-
cal complications and procedural complications such as 
bleeding. Interestingly, consistent with previous studies, we 
found that elderly patients were less likely to develop stent 
Fig. 3 Probability of 3-year 
mortality, major adverse cardiac 
events, stroke, and BARC bleed-
ing ≥ 3 according to age. MACE 
major adverse cardiovascular 
event, BARC bleeding academic 
research consortium
 
Fig. 2 Kaplan-Meier curve for 
recurrent myocardial infarction, 
mortality, BARC bleeding ≥ 3, 
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more effective in inhibiting platelet aggregation compared 
with clopidogrel may also cause more bleeding events in 
the elderly, potentially offsetting the reduction in ischaemic 
events observed in randomised controlled trials. Ideally, this 
should be investigated in a randomised clinical trial enroll-
ing STEMI patients aged ≥ 80 years.
Limitations
A number of limitations of the present study deserve men-
tioning. First, only a relatively small cohort of patients aged 
≥ 80 years were included in the present analysis. Nonethe-
less, this is the largest cohort of very elderly patients to date 
with detailed reporting of a multitude of 3-year ischaemic 
and bleeding events. Moreover, due to the high event rates, 
this cohort was sufficiently powered to conduct multivari-
able analyses. Finally, as this was an observational study we 
can only speculate about treatment strategies to improve the 
clinical outcome of very elderly patients undergoing primary 
PCI.
Conclusion
Patients ≥ 80 years experienced high rates of ischaemic and 
bleeding complications, especially in this high-risk patient 
group individualised therapy is needed to optimise clinical 
outcomes.
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